aminolevulinic acid has been researched along with Keratosis, Oral in 28 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a 42-year-old man with concomitant oral leukoplakia and oral submucous fibrosis almost involving the entire right buccal mucosa, who underwent six sessions of topical 5-aminolevulinic acid-mediated photodynamic therapy." | 8.31 | 5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report. ( Fang, C; Gao, X; Jiang, C; Li, N; Ma, L; Peng, J; Song, S; Wan, W, 2023) |
| "In conclusion, topical 5-aminolevulinic acid-mediated photodynamic therapy appears safe and has excellent clinical efficacy against oral leukoplakia-concomitant oral submucous fibrosis, but long-term follow-up is necessary." | 8.31 | 5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report. ( Fang, C; Gao, X; Jiang, C; Li, N; Ma, L; Peng, J; Song, S; Wan, W, 2023) |
| "Our recent studies showed that a new topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) protocol using a light-emitting diode (LED) light source is an effective and successful treatment modality for five cases of oral verrucous hyperplasia (OVH) and one case of verrucous carcinoma." | 7.73 | Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. ( Chen, HM; Chiang, CP; Tsai, T; Tu, PC; Yeh, CY; Yu, CH, 2005) |
| "We report the case of a 42-year-old man with concomitant oral leukoplakia and oral submucous fibrosis almost involving the entire right buccal mucosa, who underwent six sessions of topical 5-aminolevulinic acid-mediated photodynamic therapy." | 4.31 | 5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report. ( Fang, C; Gao, X; Jiang, C; Li, N; Ma, L; Peng, J; Song, S; Wan, W, 2023) |
| "In conclusion, topical 5-aminolevulinic acid-mediated photodynamic therapy appears safe and has excellent clinical efficacy against oral leukoplakia-concomitant oral submucous fibrosis, but long-term follow-up is necessary." | 4.31 | 5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report. ( Fang, C; Gao, X; Jiang, C; Li, N; Ma, L; Peng, J; Song, S; Wan, W, 2023) |
| "Our previous studies showed that topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) is very effective for oral verrucous hyperplasia (OVH) and relatively less effective for oral leukoplakia (OL) lesions." | 3.79 | Expression of Bak and Bak/Mcl-1 ratio can predict photodynamic therapy outcome for oral verrucous hyperplasia and leukoplakia. ( Chen, HM; Chiang, CP; Lin, HP; Yu, CH, 2013) |
| "Our recent studies showed that a new topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) protocol using a light-emitting diode (LED) light source is an effective and successful treatment modality for five cases of oral verrucous hyperplasia (OVH) and one case of verrucous carcinoma." | 3.73 | Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. ( Chen, HM; Chiang, CP; Tsai, T; Tu, PC; Yeh, CY; Yu, CH, 2005) |
| "Oral leukoplakia is a pre-malignant lesion of the oral mucosa." | 2.77 | Comparison of cryotherapy and photodynamic therapy in treatment of oral leukoplakia. ( Kawczyk-Krupka, A; Kościarz-Grzesiok, A; Koszowski, R; Kwiatek, S; Latos, W; Raczkowska-Siostrzonek, A; Sieroń, A; Straszak, D; Waśkowska, J, 2012) |
| "A new therapy for the treatment of oral leukoplakia by 5-aminolevulinic acid (ALA) and photodynamic therapy (PDT) is presented." | 2.69 | Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid. ( Barth, T; Haase, T; Kübler, A; Mühling, J; Rheinwald, M, 1998) |
| "The reported numbers of PMDS and HNSCC ranged between 5 and 225." | 2.58 | Photodynamic treatment outcomes of potentially-malignant lesions and malignancies of the head and neck region: A systematic review. ( Choudhary, MG; Gadbail, AR; Gondivkar, SM; Likhitkar, MS; Vedpathak, PR, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 8 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, Y | 2 |
| Shi, L | 2 |
| Wang, Y | 1 |
| Shen, X | 2 |
| Ye, S | 1 |
| Tang, G | 2 |
| Wu, L | 2 |
| Zhang, Q | 1 |
| Wang, F | 1 |
| Liang, J | 1 |
| Kuang, W | 1 |
| Zeng, X | 3 |
| Zhang, X | 1 |
| Ou, J | 1 |
| Gao, Y | 1 |
| Li, H | 1 |
| Ling, T | 1 |
| Xie, X | 1 |
| Yan, Y | 1 |
| Li, Z | 1 |
| Tian, X | 1 |
| Chen, Q | 2 |
| Wang, J | 2 |
| Du, Y | 1 |
| Yang, C | 1 |
| Xu, P | 1 |
| Wan, W | 3 |
| Gao, X | 3 |
| Song, S | 3 |
| Peng, J | 3 |
| Jiang, C | 3 |
| Fang, C | 3 |
| Li, N | 3 |
| Ma, L | 3 |
| Swapna, LA | 2 |
| Alawad, AO | 2 |
| Abdullah AlAmri, L | 2 |
| Sayed Abdul, N | 2 |
| Qamar, Z | 2 |
| Vempalli, S | 2 |
| Niazi, FH | 2 |
| Gondivkar, SM | 1 |
| Gadbail, AR | 1 |
| Choudhary, MG | 1 |
| Vedpathak, PR | 1 |
| Likhitkar, MS | 1 |
| Jurczyszyn, K | 1 |
| Kazubowska, K | 1 |
| Kubasiewicz-Ross, P | 1 |
| Ziółkowski, P | 1 |
| Dominiak, M | 1 |
| Wang, X | 1 |
| Han, Y | 1 |
| Jin, J | 1 |
| Cheng, Z | 1 |
| Wang, Q | 1 |
| Guo, X | 1 |
| Li, W | 1 |
| Liu, H | 1 |
| Dan, H | 1 |
| Tang, F | 1 |
| Li, X | 1 |
| Cheng, J | 1 |
| Zhao, H | 1 |
| Wong, SJ | 1 |
| Campbell, B | 1 |
| Massey, B | 1 |
| Lynch, DP | 1 |
| Cohen, EEW | 1 |
| Blair, E | 1 |
| Selle, R | 1 |
| Shklovskaya, J | 1 |
| Jovanovic, BD | 1 |
| Skripkauskas, S | 1 |
| Dew, A | 1 |
| Kulesza, P | 1 |
| Parimi, V | 1 |
| Bergan, RC | 1 |
| Szabo, E | 1 |
| Chen, HM | 6 |
| Cheng, SJ | 1 |
| Chiang, CP | 6 |
| Rosin, FC | 1 |
| Barcessat, AR | 1 |
| Borges, GG | 1 |
| Ferreira, LG | 1 |
| Corrêa, L | 1 |
| Yu, CH | 4 |
| Lin, HP | 3 |
| Yang, H | 2 |
| Wang, YP | 2 |
| Jerjes, W | 1 |
| Upile, T | 1 |
| Hamdoon, Z | 1 |
| Mosse, CA | 1 |
| Akram, S | 1 |
| Hopper, C | 1 |
| Shafirstein, G | 1 |
| Friedman, A | 1 |
| Siegel, E | 1 |
| Moreno, M | 1 |
| Bäumler, W | 1 |
| Fan, CY | 1 |
| Morehead, K | 1 |
| Vural, E | 1 |
| Stack, BC | 1 |
| Suen, JY | 1 |
| Kawczyk-Krupka, A | 2 |
| Waśkowska, J | 1 |
| Raczkowska-Siostrzonek, A | 1 |
| Kościarz-Grzesiok, A | 1 |
| Kwiatek, S | 1 |
| Straszak, D | 1 |
| Latos, W | 1 |
| Koszowski, R | 1 |
| Sieroń, A | 2 |
| Adamek, M | 1 |
| Mazur, S | 1 |
| Ilewicz, L | 1 |
| Tsai, JC | 1 |
| Huang, SB | 1 |
| Wang, CW | 1 |
| Lee, MI | 1 |
| Hsu, YC | 1 |
| Chen, CT | 1 |
| Tsai, T | 2 |
| Tu, PC | 1 |
| Yeh, CY | 1 |
| Franco, RA | 1 |
| Kübler, A | 1 |
| Haase, T | 1 |
| Rheinwald, M | 1 |
| Barth, T | 1 |
| Mühling, J | 1 |
| Leunig, A | 1 |
| Betz, CS | 1 |
| Baumgartner, R | 1 |
| Grevers, G | 1 |
| Issing, WJ | 1 |
| Karrer, S | 1 |
| Szeimies, RM | 1 |
| Hohenleutner, U | 1 |
| Landthaler, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Combined Phase I/II Single Site Study to Determine the Safety and Efficacy of Photodynamic Therapy (PDT) Utilizing 5-aminolevulinic Acid (5-ALA) and PDT in the Treatment of Premalignant Oral and/or Oropharynx Lesions.[NCT00571974] | Phase 1/Phase 2 | 29 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The traditional 3+3 dose escalation design was employed. Three cohorts were enrolled at 3 subjects per cohort, and treated with escalating radiant exposures of 6, 7, or 8 J/cm2. In each cohort, the number of dose-limiting toxicities (DLTs) were observed. Dose escalation rules were the same as those provided by Storer 1989. (NCT00571974)
Timeframe: Day 2
| Intervention | J/cm2 (Number) |
|---|---|
| Phase I | 8 |
The response rate was quantified by examination by an experienced head and neck surgeon and classified as follows: significant response (SR) was one where the lesion had greater than 75% resolution, partial response (PR) was one in which the lesion was reduced in size by at least 25%, and no response (NR) was one where the lesion was reduced by less than 25% in size. (NCT00571974)
Timeframe: Day 90
| Intervention | participants (Number) | ||
|---|---|---|---|
| Participants with Significant Response (SR) | Participants with Partial Response (PR) | Participants with no Response (NR) | |
| Phase II | 7 | 9 | 1 |
3 reviews available for aminolevulinic acid and Keratosis, Oral
| Article | Year |
|---|---|
Photodynamic treatment outcomes of potentially-malignant lesions and malignancies of the head and neck region: A systematic review.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Chlorophyllides; Databases, Factual; Dihematoporphyri | 2018 |
Photodynamic therapy guidelines for the management of oral leucoplakia.
Topics: Aminolevulinic Acid; Humans; Leukoplakia, Oral; Photochemotherapy; Photosensitizing Agents; Practice | 2019 |
Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy.
Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinica | 2001 |
8 trials available for aminolevulinic acid and Keratosis, Oral
| Article | Year |
|---|---|
Ablative fractional laser-assisted photodynamic therapy vs. ablative fractional laser for oral leukoplakia treatment: A randomized, controlled pilot study.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Humans; Laser Therapy; Lasers, Solid-State; Leukoplak | 2021 |
Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy in patients with nicotine stomatitis.
Topics: Aminolevulinic Acid; Humans; Leukoplakia, Oral; Nicotine; Photochemotherapy; Photosensitizing Agents | 2023 |
Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy in patients with nicotine stomatitis.
Topics: Aminolevulinic Acid; Humans; Leukoplakia, Oral; Nicotine; Photochemotherapy; Photosensitizing Agents | 2023 |
Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy in patients with nicotine stomatitis.
Topics: Aminolevulinic Acid; Humans; Leukoplakia, Oral; Nicotine; Photochemotherapy; Photosensitizing Agents | 2023 |
Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy in patients with nicotine stomatitis.
Topics: Aminolevulinic Acid; Humans; Leukoplakia, Oral; Nicotine; Photochemotherapy; Photosensitizing Agents | 2023 |
A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia.
Topics: Aminolevulinic Acid; Humans; Leukoplakia, Oral; Photochemotherapy; Photosensitizing Agents | 2013 |
Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Erythroplasia; Female; Follow-Up Studies; Human | 2009 |
Photodynamic therapy outcome for oral dysplasia.
Topics: Aged; Aminolevulinic Acid; Carcinoma in Situ; Drug Administration Schedule; Female; Humans; Lasers, | 2011 |
Using 5-aminolevulinic acid and pulsed dye laser for photodynamic treatment of oral leukoplakia.
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Biopsy; Dose-Response Relationship, Drug; | 2011 |
Comparison of cryotherapy and photodynamic therapy in treatment of oral leukoplakia.
Topics: Adult; Aged; Aminolevulinic Acid; Cryosurgery; Cryotherapy; Female; Humans; Leukoplakia, Oral; Male; | 2012 |
Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Argon; Female; Humans; Laser Therapy; Leukoplak | 1998 |
17 other studies available for aminolevulinic acid and Keratosis, Oral
| Article | Year |
|---|---|
Photodynamic therapy for extensive oral verrucous/granular leukoplakia with moderate-to-severe dysplasia: A case study.
Topics: Aminolevulinic Acid; Cell Transformation, Neoplastic; Humans; Leukoplakia, Oral; Male; Middle Aged; | 2022 |
Application of 5-aminolevulinic acid-mediated Waterlase-assisted photodynamic therapy in the treatment of oral leukoplakia.
Topics: Aminolevulinic Acid; Humans; Hyperplasia; Leukoplakia, Oral; Photochemotherapy; Photosensitizing Age | 2022 |
Laser-assisted photodynamic therapy in proliferative verrucous oral leukoplakia.
Topics: Aminolevulinic Acid; Humans; Lasers; Leukoplakia, Oral; Neoplasms; Photochemotherapy; Photosensitizi | 2022 |
Photodynamic therapy with 20% aminolevulinic acid administered externally in the treatment of oral leukoplakia.
Topics: Aminolevulinic Acid; Humans; Leukoplakia, Oral; Photochemotherapy | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report.
Topics: Adult; Aminolevulinic Acid; Humans; Leukoplakia, Oral; Male; Mouth Neoplasms; Oral Submucous Fibrosi | 2023 |
The combination of photodynamic therapy and fractional CO
Topics: Aminolevulinic Acid; Carbon Dioxide; Humans; Laser Therapy; Leukoplakia, Oral; Neoplasm Recurrence, | 2020 |
Application of fractal dimension analysis and photodynamic diagnosis in the case of differentiation between lichen planus and leukoplakia: A preliminary study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Fractals; Humans; Leuk | 2018 |
Plum-blossom needle assisted photodynamic therapy for the treatment of oral potentially malignant disorder in the elderly.
Topics: Aged; Aminolevulinic Acid; Combined Modality Therapy; Flowers; Humans; Leukoplakia, Oral; Male; Need | 2019 |
Topical photodynamic therapy is the first-line treatment of choice for oral erythroleukoplakia and oral verrucous hyperplasia.
Topics: Aminolevulinic Acid; Carcinoma, Verrucous; Humans; Hyperplasia; Leukoplakia, Oral; Mouth; Photochemo | 2015 |
Vascular alterations after photodynamic therapy mediated by 5-aminolevulinic acid in oral leukoplakia.
Topics: 4-Nitroquinoline-1-oxide; Aminolevulinic Acid; Animals; Humans; Immunohistochemistry; Leukoplakia, O | 2017 |
Topical photodynamic therapy is very effective for oral verrucous hyperplasia and oral erythroleukoplakia.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Erythroplasia; Femal | 2010 |
Expression of Bak and Bak/Mcl-1 ratio can predict photodynamic therapy outcome for oral verrucous hyperplasia and leukoplakia.
Topics: Adult; Aged; Aminolevulinic Acid; bcl-2 Homologous Antagonist-Killer Protein; Biomarkers; Biopsy; Ca | 2013 |
Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia.
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Humans; Laser Therapy; Leukoplakia, Oral; | 2003 |
Photodynamic Therapy of oral dysplasia with topical 5-aminolevulinic acid and light-emitting diode array.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Animals; Cricetinae; Equipment Design; Female; | 2004 |
Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy.
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Carcinoma, Verrucous; Drug Administration | 2005 |
Aminolevulinic acid 585 nm pulsed dye laser photodynamic treatment of laryngeal keratosis with atypia.
Topics: Administration, Topical; Aged; Ambulatory Care; Aminolevulinic Acid; Biopsy; Cell Transformation, Ne | 2007 |
Initial experience in the treatment of oral leukoplakia with high-dose vitamin A and follow-up 5-aminolevulinic acid induced protoporphyrin IX fluorescence.
Topics: Adult; Aminolevulinic Acid; Anticarcinogenic Agents; Diterpenes; Female; Fluorescence; Humans; Leuko | 2000 |